Panel for clearance of new drugs

2304. SHRI KHAN GHUFRAN ZAHIDI: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that DGHS is proposing to form a panel for clearance of the new drugs; and

(b) if so, the composition of the panel?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI A. RAJA): (a) and (b) Expert Panels already exist for clearance of new drugs. These are as follows:

1. Expert Panel for evaluation of Investigational New Drug Molecule, constituted in January, 2001.
2. Expert Panel for evaluation of Recombinant DNA therapeutic products constituted in March, 2001.

Composition of both panels is given in Statement-I and II respectively.

Statement

Expert Panel for evaluation of Investigational New Drug Molecule constituted in January, 2001.

1. Dr. N.K. Ganguly, Director General, ICMR, New Delhi	.....	Chairman
2. Dr. J.N. Pandey, Prof. & Head, Deptt. of Medicine, AIIMS, New Delhi.	.....	Member
3. Dr. S.D. Seth, Emeritus Scientist, Pharmacologist & Consultant, ICMR	.....	Member
4. Dr. Nilima Kshirsagar, Pharmacologist, Dean, PYL, Nair Hospital, Mumbai	.....	Member

5. Prof. Gopal Prasad Sinha, Prof. of Medicine, Patna Medical College, Patna	.....	Member
6. Dr. Ajay Kumar (Urologist), President, IMA, Patna	.....	Member
7. Prof. P. Rama Rao, Deptt. of Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)	.....	Member
8. Dr. M.K. Gurjar, Dy. Director, Organic Chemistry, National Chemical Lab, Pune	.....	Member
9. Dr. Sudhir Srivastava, Scientist in charge, Div. of Toxicology, CDRI, Lucknow.	.....	Member
10. Dr. S. Majumdar, Head, Deptt. of Experimental Medicine, PGI. Chandigarh.	.....	Member
11. Dr. Vasantha Muthuswamy, DDG, ICMR, New Delhi	.....	Member
12. DCG(I), Dte. of GHS	.....	Convenor

Statement-II

Expert Panel for evaluation of Recombinant DNA therapeutic products constituted in March, 2001

1. Dr. Y.N. Rao, Officer on Special Duty, Dte. of GHS
2. Dr. Y.D. Sharma, Head of Deptt., Biotechnology, All India Institute of Medical Sciences.
3. Dr. S.S. Agarwal, Prof. Medical Genetics, Sanjay Gandhi Post-graduate Institute, Lucknow.

4. Director, National Institute of Biologicals (NIB) or its representative.
5. Representative from Deptt. of Biotechnology.
6. Dr. S. Majumdar, Prof. Biotechnology, Post Graduate Institute, Chandigarh.
7. Dr. S. Brahmachari, Centre for Biotechnology, Delhi University.
8. Drugs Controller General of India.....Convener.

Trauma Centre at AIIMS

†2305. SHRI KHAN GHUFRAN ZAHIDI: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Government are aware of the delay in the construction of the trauma centre in the All India Institute of Medical Sciences; and

(b) if so, the reasons therefor and the steps being taken to complete this work within the time frame?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI A. RAJA): (a) and (b) The proposal for construction of Trauma Centre at AIIMS at an estimated cost of Rs. 54.14 crore was approved in September, 2001. The work was expected to be completed in 33 months i.e. by September, 2004. However the completion period was subsequently shortened to 24 months. Because of the change in scope of work, the Revised Cost Estimates require approval of the competent authority. To monitor the timely completion of the project, a Project Implementation Committee & Technical Committee consisting of multi disciplinary team of experts has been constituted.

Research in Ayurvedic & Homoeopathic Medicines

2306. SHRI MANOJ BHATTACHARYA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that the National Institute of Homoeopathy, Kolkata and the National Institute of Ayurveda, Jaipur are functioning under the administrative control of her Ministry;

†Original notice of the question was received in Hindi.